On 10/29/19, NEW CORP PRESENTATION SAYS WAITING ON 298!!!!


****INSIDER BUYS****

 "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise." - Peter Lynch 


On 10/25, Geert bought another $25K!


On 9/4, the Geert and 2 others purchased another $57K. 


On  6/3,  Geert  bought  MORE!  He  bought  another $25K


On 5/7,  Geert "purchased another $100,000 worth of restricted CEL-SCI stock at $6.86 directly from the Company at the full market price. Several others from our senior management team and one member of the Board of Directors have joined  Geert and purchased another $110,000 worth of CEL-SCI stock on the same terms. "


Furthermore, on 5/21 Peter Young bought another $10K on the open market.


All Insider Transactions can be seen here.

IDMC SAYS CONTINUE!!!!

 The IDMC made the following recommendation on October 15, 2019 


  • The IDMC recommendation “is to continue the trial until the appropriate number of events has occurred”.


The subsequent  8-K said it more succinctly:


  • The IDMC "Recommended to continue the trial until the appropriate number of events has occurred."


READ ABOUT THE IDMC HERE

9/25: ERGOMED SAYS STUDY IS 96% COMPLETE OR DID THEY??

On 9/25, Ergomed released their Interim financial results.  In this presentation, they state the following:


  •  Awaiting Phase III results 
  •  Limited work ongoing on 30 day terms and paid from share sales 
  • 96% complete  


96% complete...not 95% or "First Half of 2019" (like their prior presentation), but 96%.  Why not 95%?


This implies we are at 286 Events!  FOSCO is RIGHT!!!!


******BUT WAIT!!!  Shortly after posting this all over the internet, the Interim Presentation was REMOVED and UPDATED.  It no longer mentions "96% Complete".  


Don't worry, your pal Sushi kept a copy here!


Why did they remove 96%?  Because they fucked up and accidentally released CONFIDENTIAL info.  That's why!


READ THE AMAZING ARTICLE BELOW

CNBC'S JIM CRAMER MENTIONS CEL-SCI!!!!!

On September 23, CNBC's Jim Cramer gives a ***BUY*** for CVM!!!


CRAMER: “It’s just a good spec.” 

image1

CT SITE IS UPDATED ON 10/1/19

DECEMBER 19 IS NOW THE ANTICIPATED END DATE

On 10/1/2019, the Clinical Trial site was updated.  The previous anticipated end date was September 2019.


It is now states an anticipated end date of December 2019!

MULTIKINE.COM DOMAIN HAS A NEW OWNER!

Andybo from StockTwits brought this to our attention.   Someone bought out the domain name Multikine.com on Friday, Sept 13 before the expiration date, meaning, someone paid $ to buy out the domain from the old owner.  Why now? Why days before the IDMC did this happen?


Who is the new owner?  Multikine.com doesn't redirect to the Cel-Sci.com website....


While we dont know now, time will tell.  Things like this are called "HINTS" 

HC WAINWRIGHT CONFERENCE SUMMARY

On 9/10, Geert presented at the HC Wainright sponsored conference.  Here are the key takeaways:


  • Still waiting on the 298th event.
  • Bristol-Myers' drug Ipilimumab also had similar Event-Driven trial "delays".  It went on to be a blockbuster drug.
  • CEL-SCI management has outsourced their survival analysis to a third party and has determined that the SOC has gotten WORSE.  This bodes well for all the various analyses. The team of Fosco Research and North Shore Research put their heads together and wrote this new article: HERE


CASH CASH BABY

The 6/30/19 10Q detailed we have over $12M in cash to work with due to the high amounts of warrants converted!


***NO CASH RAISE/DILUTION UNTIL AT LEAST FEB 2020!***

BLACKROCK ADDS 1.3M SHARES

BLACKROCK ADDED 1.3M SHARES LAST QUARTER PER THEIR 13F. THEY NOW HAVE OVER 1.8M SHARES.

LEAKS?

Some of you say there should be "leaks" of how the Trial is coming....So here is one.


From the 10/2/2015 Minutes of Aintree HaNC Patient Research Forum, a CT Site: 


 "...Observed effects of the drug have shown significant reduction in size of tumour." 


HELLO RUSSELL 2000!

Big Day on 6/28! Over 3M Shares put into the Russell 2000 and related indexes for 1 YEAR!!


 PR from CEL-SCI ABOUT JOINING THE R2K INDEX HERE


There was massive Index buying afterhours on June 28th and over 3M shares are now locked down for 1 year.  They are now effectively removed from the float.


This decreases the supply.  What happens to prices when supply decreases?


Ergomed Insider Transactions

 Dr Miroslav Reljanovic, Executive Chairman of the Company, purchased 200K shares ($775K USD) on 6/24.  Add this to the recent purchases by the COO and CFO brings the total to over $1.2M USD of Insider transactions in the past weeks.


Insider transactions details HERE


For a Deep Dive on the Ergomed and CEL-SCI relationship, please read this Article HERE

CEL-SCI IS HIRING!!!!!!!

Why is a Biotech with limited cash resources hiring 3 operational positions? Why would they incur the costs to hire, train and pay new employees this late?

Why do they think they need OPERATIONAL positions?


This is not normal...This is BULLISH!!!!!


Career Page

Our 15 Minutes of Fame

Aren't we something?  Watch this video talking all about this site!  

SeekingAlpha Articles are Great!

With much effort, our team has published the following articles on SeekingAlpha: 


 


THESE ARE MUST READS!

THE IDMC NEWS WAS HUGE

On 3/29/19, Cel-Sci released a PR stating that the IDMC has done their recent interim review and they made the following recommendation:


"continue the trial until the appropriate number of events have occurred."


PRESS RELEASE HERE


This is a big fucking deal!  At this point in the 8 year study, they have about 95% of all the data.  They would know if the study was futile or not.  If it was futile, they would have shut it down.


In the last 2 weeks the IDMC has shut down 3 trials for FUTILITY.  CVM just had the IDMC review their Phase III study for futility and recommended the trial should continue.  The 3 PRs link below are from the 3 recent trials that were just shut down:


 PRESS RELEASE HERE 

 

PRESS RELEASE HERE


PRESS RELEASE HERE


Full-Scale Manufacturing Facility Tour

 CEL-SCI operates its own 73,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. About $100M was spent on the manufacturing plant, development and validation. 


Manufacturing in-house helps them protect their IP and allows for more control when working with the FDA and other regulators to secure approval of Multikine. 


Read All About the Recent Tour to the Facility HERE